Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension

Lauren Brash; Gareth D. Barnes; Melanie J. Brewis; A. Colin Church; Simon J. Gibbs; Luke S.G.E. Howard; Geeshath Jayasekera; Martin K. Johnson; Neil McGlinchey; Joelle Onorato; Joanne  Simpson; Colin Stirrat; Stephen Thomson; Geoffrey  Watson; Martin R. Wilkins; Carrie Xu; David J. Welsh; David E. Newby; Andrew J. Peacock

doi:10.1016/j.jacbts.2018.01.013

Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension

Lauren Brash, Gareth D. Barnes, Melanie J. Brewis, A. Colin Church, Simon J. Gibbs, Luke S.G.E. Howard, Geeshath Jayasekera, Martin K. Johnson, Neil McGlinchey, Joelle Onorato, Joanne Simpson, Colin Stirrat, Stephen Thomson, Geoffrey Watson, Martin R. Wilkins, Carrie Xu, David J. Welsh, David E. Newby, Andrew J. Peacock^*

^*Corresponding author for this work

Biological and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

101 Downloads (Pure)

Abstract

Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr ¹)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr ¹)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH.

Original language	English
Pages (from-to)	176-186
Number of pages	11
Journal	JACC: Basic to Translational Science
Volume	3
Issue number	2
Early online date	28 Mar 2018
DOIs	https://doi.org/10.1016/j.jacbts.2018.01.013
Publication status	Published - Apr 2018

Keywords

apelin pulmonary hypertension
apelin
APJ
human
pulmonary arterial hypertension

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Documents and Links

10.1016/j.jacbts.2018.01.013

Brash, L. et al (2018) Short-Term Hemodynamic Effectsof Apelin in Patients With Pulmonary Arterial Hypertension
Copyright © 2018 The authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the cc -by-nc-nd license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Final published version, 1.05 MBLicence: CC BY-NC-ND

David Welsh
- dwe2gcu.acuk
- Biological and Biomedical Sciences - Reader
Person

Cite this

Brash, L., Barnes, G. D., Brewis, M. J., Church, A. C., Gibbs, S. J., Howard, L. S. G. E., Jayasekera, G., Johnson, M. K., McGlinchey, N., Onorato, J., Simpson, J., Stirrat, C., Thomson, S., Watson, G., Wilkins, M. R., Xu, C., Welsh, D. J., Newby, D. E., & Peacock, A. J. (2018). Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension. JACC: Basic to Translational Science, 3(2), 176-186. https://doi.org/10.1016/j.jacbts.2018.01.013

@article{b0db874399d84a4cbea355f3ae6ef8c4,

title = "Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension",

abstract = "Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr 1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr 1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH.",

keywords = "apelin pulmonary hypertension, apelin, APJ, human, pulmonary arterial hypertension",

author = "Lauren Brash and Barnes, {Gareth D.} and Brewis, {Melanie J.} and Church, {A. Colin} and Gibbs, {Simon J.} and Howard, {Luke S.G.E.} and Geeshath Jayasekera and Johnson, {Martin K.} and Neil McGlinchey and Joelle Onorato and Joanne Simpson and Colin Stirrat and Stephen Thomson and Geoffrey Watson and Wilkins, {Martin R.} and Carrie Xu and Welsh, {David J.} and Newby, {David E.} and Peacock, {Andrew J.}",

note = "Acceptance from webpage Exception 254a applied in error, author affiliated to NHS hospital on VoR. Exception email to author. 18/1/21 ^No response from author before deadline, added 'no exception'. ET 22/1/21 As this is published 'OA' no check in other rep. ET 25/1/21",

year = "2018",

month = apr,

doi = "10.1016/j.jacbts.2018.01.013",

language = "English",

volume = "3",

pages = "176--186",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "2",

}

Brash, L, Barnes, GD, Brewis, MJ, Church, AC, Gibbs, SJ, Howard, LSGE, Jayasekera, G, Johnson, MK, McGlinchey, N, Onorato, J, Simpson, J, Stirrat, C, Thomson, S, Watson, G, Wilkins, MR, Xu, C, Welsh, DJ, Newby, DE & Peacock, AJ 2018, 'Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension', JACC: Basic to Translational Science, vol. 3, no. 2, pp. 176-186. https://doi.org/10.1016/j.jacbts.2018.01.013

TY - JOUR

T1 - Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension

AU - Brash, Lauren

AU - Barnes, Gareth D.

AU - Brewis, Melanie J.

AU - Church, A. Colin

AU - Gibbs, Simon J.

AU - Howard, Luke S.G.E.

AU - Jayasekera, Geeshath

AU - Johnson, Martin K.

AU - McGlinchey, Neil

AU - Onorato, Joelle

AU - Simpson, Joanne

AU - Stirrat, Colin

AU - Thomson, Stephen

AU - Watson, Geoffrey

AU - Wilkins, Martin R.

AU - Xu, Carrie

AU - Welsh, David J.

AU - Newby, David E.

AU - Peacock, Andrew J.

N1 - Acceptance from webpage Exception 254a applied in error, author affiliated to NHS hospital on VoR. Exception email to author. 18/1/21 ^No response from author before deadline, added 'no exception'. ET 22/1/21 As this is published 'OA' no check in other rep. ET 25/1/21

PY - 2018/4

Y1 - 2018/4

N2 - Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr 1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr 1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH.

AB - Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr 1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr 1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH.

KW - apelin pulmonary hypertension

KW - apelin

KW - APJ

KW - human

KW - pulmonary arterial hypertension

U2 - 10.1016/j.jacbts.2018.01.013

DO - 10.1016/j.jacbts.2018.01.013

M3 - Article

C2 - 29876530

VL - 3

SP - 176

EP - 186

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

SN - 2452-302X

IS - 2

ER -